Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.18
−$0.06 · -4.84%
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
Previous close
$1.18
−$0.06 · -4.84%
Regular session · ET · Market data may be delayed.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
Day range
Current $1.18
52-week range
Current $1.18
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
32
Expensive
Sentiment
54
Mixed
Risk
76
High Risk
Momentum
53
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
Day range
Current $1.18
52-week range
Current $1.18
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 6.59M USD | 3.31M USD | 3.51M USD | 1.24M USD |
| Cost of goods sold | — | 13.47M USD | 10.42M USD | 11.97M USD | 3.16M USD |
| Gross profit | — | −6.88M USD | −7.11M USD | −8.45M USD | −1.92M USD |
| Research and development | 11.8M USD | 13.47M USD | 10.42M USD | 11.97M USD | 27.79M USD |
| Selling, general, and administrative | 4.18M USD | 4.24M USD | 7.48M USD | 11.34M USD | 9.76M USD |
| Operating expenses | 12.89M USD | 4.24M USD | 7.48M USD | 11.34M USD | 37.56M USD |
| Interest income | 594.21K USD | 437.01K USD | 539.16K USD | 248.06K USD | 5.7K USD |
| Depreciation and amortization | — | 2 USD | 2.79M USD | 2.79M USD | 3.16M USD |
| Operating income | −12.89M USD | −11.12M USD | −14.58M USD | −19.79M USD | −39.48M USD |
| Net income | −12.16M USD | −10.73M USD | −8.24M USD | −29.93M USD | −41.88M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 27, 2023 | 1:10 | — | — |
Stock split | Sep 16, 2016 | 1:12 | — | — |
Stock split | Feb 25, 2014 | 1:100 | — | — |
Stock split | Jul 27, 2009 | 1:10 | — | — |
Stock split | Apr 4, 2008 | 2:5 | — | — |
Stock split | Jun 28, 2007 | 2:5 | — | — |
Effective Jan 27, 2023
1:10
Effective Sep 16, 2016
1:12
Effective Feb 25, 2014
1:100
Effective Jul 27, 2009
1:10
Effective Apr 4, 2008
2:5
Effective Jun 28, 2007
2:5
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
